Although liver transplantation provide a option to cure patients suffering with decompensated liver cirrhosis this condition, lack of donors, postoperative complications, especially rejection, and high cost limit its application. Bone marrow derived mesenchymal stem cells (BM-MSCs) have been shown to replace hepatocytes in injured liver, effectively rescued experimental liver failure and contributed to liver regeneration, which suggest the novel and promising therapeutic strategy In this study, the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSCs) transplantation for patients with decompensated liver cirrhosis will be evaluated.

To investigate the safety and efficacy of human umbilical cord mesenchymal stem cells transplantation in patients of decompensated liver cirrhosis.

Inclusion Criteria:

• Written informed consent.
• Aged 18-70 years.
• Decompensated liver cirrhosis, Child-Pugh B/C (7-12 points); or Meld score≦21.
• Expecting lifetime is over 2 months.
• Hepatitis B decompensated liver cirrhosis patients need antiviral therapy.

Exclusion Criteria:

• Severe drug allergic history or anaphylaxis.
• Severe problems in other vital organs(e.g. the heart, renal or lungs)
• Severe problems in psychiatric disease,such as Schizophrenia,et al
• Severe bacteria infection.
• Malignancies.
• Alcoholism or drug abuse.
• Plan to have liver transplantation in 3 months.
• Pregnancy
• Candidates who are participating in other study.